Alvotech has made a significant move in the biosimilar market by submitting a regulatory application for AVT29, a proposed biosimilar to Eylea® 8 mg. This submission, made to the European Medicines Agency, is noteworthy as it represents the first known regulatory application worldwide for a biosimilar to Eylea® 8 mg. The development is expected to enhance treatment options for patients suffering from retinal diseases, potentially reducing the treatment burden associated with frequent injections.
Founded by Robert Wessman, Alvotech is a biotechnology company focused on developing and manufacturing biosimilar medicines. The company is listed on Nasdaq under the ticker symbols ALVO and ALVOW. With a strong commitment to delivering high-quality, cost-effective products, Alvotech aims to be a leader in the biosimilar space. The company is classified under the SIC code 2836, which refers to Biological Products, (No Diagnostic Substances).
The recent filing, dated October 14, 2026, indicates that Alvotech's application for AVT29 has been submitted as a line extension to its existing marketing authorization for Mynzepli® (AVT06), a biosimilar to Eylea® 2 mg. The press release accompanying the filing states, "To our knowledge, this is the first regulatory submission anywhere in the world for a proposed biosimilar to Eylea 8 mg." This milestone underscores Alvotech's robust development capabilities and its strategic focus on high-dose aflibercept formulations.
The submission could significantly impact patients who require treatment for retinal diseases, as the 8 mg formulation allows for longer treatment intervals—up to 16 weeks—compared to the standard eight-week maintenance interval of the original 2 mg formulation. This change could lead to a reduction in the frequency of maintenance injections, thereby easing the treatment burden on patients and healthcare providers.
The filing does not specify the next steps following this submission. However, it is clear that this move positions Alvotech at the forefront of the biosimilar market, especially in the context of aflibercept products. As the biosimilar landscape continues to evolve, competitors will likely need to adapt their strategies in response to Alvotech's advancements.